The document discusses key considerations for manufacturers in implementing changes required by the 2016 Medicaid Program Covered Outpatient Drug Final Rule. It identifies potential impacts to master data, price type configurations, and calculations for monthly and quarterly Average Manufacturer Price. Implementation may require modifications to product and customer masters, government pricing modules, and downstream reporting and interfaces.
Bank of America Merrill Lynch Healthcare ConferenceImpaxLaboratories
- The document is a presentation by Impax Laboratories at a health care conference discussing its business strategies and outlook.
- Impax has two platforms for growth - generics targeting $25B in US sales and brands focused on central nervous system drugs.
- Its strategies include organic growth of its generic and brand pipelines, strategic partnerships mainly for alternative dosage forms, and mergers and acquisitions mainly for alternative dosage forms.
Bank of America Merrill Lynch Health Care Conferene May 16 2013impax-labs
- The document is a presentation by Impax Laboratories at a health care conference discussing its business strategies and outlook.
- Impax has two platforms for growth - generics targeting $25B in US sales and brands focused on central nervous system drugs.
- Its strategies include organic growth of its generic and brand pipelines, strategic partnerships mainly in alternative dosage forms, and mergers and acquisitions mainly in alternative dosage forms.
Deutsche Bank Health Care Conference May 30 2013impax-labs
Impax Laboratories provided a "Safe Harbor" statement noting that statements in the presentation involving the future are forward-looking and actual results could differ. Impax is committed to improving operations by addressing FDA issues, implementing quality enhancements, and moving in the right direction. The company is positioned for future growth through two platforms - generics targeting $25B in U.S. sales and brands focused on central nervous system conditions. Impax has a diversified generic pipeline, established competencies, and financial flexibility to support growth strategies including organic growth, partnerships, and M&A.
Jefferies Global Healthcare Conference June 5 2013impax-labs
This document contains a "Safe Harbor" statement regarding forward-looking statements in the presentation. It notes several risks and uncertainties that could cause the company's future results to differ from forward-looking statements, including economic conditions, issues raised by the FDA in warning letters and observations, developing and commercializing pharmaceutical products, reductions in business with significant customers, the impact of competition, and other regulatory, legal and operational risks. It also provides an overview of the company's generic and branded product pipelines and growth strategies focusing on organic growth, partnerships, and M&A.
UBS Global Healthcare Conference May 22 2013impax-labs
- The document contains forward-looking statements about the company's future performance that involve known and unknown risks and uncertainties.
- The company has submitted responses to recent FDA observations and requested a meeting to ensure regulatory alignment. Significant improvements have been made to quality systems over the past two years.
- The company is committed to improving operations and moving in the right direction.
Icd 10 remediation for provider practices – key challenges and mitigation str...Apoorv S
This document discusses the key challenges providers face in transitioning from ICD-9 to ICD-10 coding standards. It identifies increased documentation specificity, reduced coding productivity, impacts to reimbursement methods, and ensuring vendor and system readiness as major challenges. Mitigation strategies discussed include clinician education, dual coding, leveraging automated coding tools, testing reimbursement impacts and collaborating closely with vendors on remediation timelines.
33rd Annual J.P. Morgan Healthcare Conferenceimpax-labs
This document contains forward-looking statements about Impax Laboratories' presentation at the 33rd Annual J.P. Morgan Healthcare Conference on January 13, 2015. The summary discusses Impax's focus on quality improvements, commercial success in 2014, proposed acquisition of CorePharma, and multiple opportunities to drive growth through their generic pipeline, RYTARY, business development, and a strong balance sheet. The acquisition of CorePharma is highlighted as expanding Impax's generic and branded portfolios and pipeline while growing and diversifying its revenue base.
Regulatory Affairs Excellence: Staffing and Performance in Medical Device Com...Best Practices
Regulatory affairs group ensure that medical device companies comply with volatile regulatory environment pertaining to developing and marketing medical device products. These specialized groups rely on their own internal effectiveness and efficiencies for enhanced performance under stringent compliance norms. Also, optimal resourcing and staffing helps Regulatory Affairs groups in the medical device industry prioritize roles and responsibilities that will be most beneficial to growth.
Best Practices, LLC conducted this benchmarking study to establish meaningful metrics and insights around the structure, activities, roles and responsibilities of Regulatory Affairs groups at medical device companies. The study also provides recent spend and staffing trends of regulatory affairs in medical device sector, including the use of outsourcing and off-shoring.
Medical device regulatory leaders can use this study to align their staff as per strategies of best in class companies for an increased performance delivery.
Bank of America Merrill Lynch Healthcare ConferenceImpaxLaboratories
- The document is a presentation by Impax Laboratories at a health care conference discussing its business strategies and outlook.
- Impax has two platforms for growth - generics targeting $25B in US sales and brands focused on central nervous system drugs.
- Its strategies include organic growth of its generic and brand pipelines, strategic partnerships mainly for alternative dosage forms, and mergers and acquisitions mainly for alternative dosage forms.
Bank of America Merrill Lynch Health Care Conferene May 16 2013impax-labs
- The document is a presentation by Impax Laboratories at a health care conference discussing its business strategies and outlook.
- Impax has two platforms for growth - generics targeting $25B in US sales and brands focused on central nervous system drugs.
- Its strategies include organic growth of its generic and brand pipelines, strategic partnerships mainly in alternative dosage forms, and mergers and acquisitions mainly in alternative dosage forms.
Deutsche Bank Health Care Conference May 30 2013impax-labs
Impax Laboratories provided a "Safe Harbor" statement noting that statements in the presentation involving the future are forward-looking and actual results could differ. Impax is committed to improving operations by addressing FDA issues, implementing quality enhancements, and moving in the right direction. The company is positioned for future growth through two platforms - generics targeting $25B in U.S. sales and brands focused on central nervous system conditions. Impax has a diversified generic pipeline, established competencies, and financial flexibility to support growth strategies including organic growth, partnerships, and M&A.
Jefferies Global Healthcare Conference June 5 2013impax-labs
This document contains a "Safe Harbor" statement regarding forward-looking statements in the presentation. It notes several risks and uncertainties that could cause the company's future results to differ from forward-looking statements, including economic conditions, issues raised by the FDA in warning letters and observations, developing and commercializing pharmaceutical products, reductions in business with significant customers, the impact of competition, and other regulatory, legal and operational risks. It also provides an overview of the company's generic and branded product pipelines and growth strategies focusing on organic growth, partnerships, and M&A.
UBS Global Healthcare Conference May 22 2013impax-labs
- The document contains forward-looking statements about the company's future performance that involve known and unknown risks and uncertainties.
- The company has submitted responses to recent FDA observations and requested a meeting to ensure regulatory alignment. Significant improvements have been made to quality systems over the past two years.
- The company is committed to improving operations and moving in the right direction.
Icd 10 remediation for provider practices – key challenges and mitigation str...Apoorv S
This document discusses the key challenges providers face in transitioning from ICD-9 to ICD-10 coding standards. It identifies increased documentation specificity, reduced coding productivity, impacts to reimbursement methods, and ensuring vendor and system readiness as major challenges. Mitigation strategies discussed include clinician education, dual coding, leveraging automated coding tools, testing reimbursement impacts and collaborating closely with vendors on remediation timelines.
33rd Annual J.P. Morgan Healthcare Conferenceimpax-labs
This document contains forward-looking statements about Impax Laboratories' presentation at the 33rd Annual J.P. Morgan Healthcare Conference on January 13, 2015. The summary discusses Impax's focus on quality improvements, commercial success in 2014, proposed acquisition of CorePharma, and multiple opportunities to drive growth through their generic pipeline, RYTARY, business development, and a strong balance sheet. The acquisition of CorePharma is highlighted as expanding Impax's generic and branded portfolios and pipeline while growing and diversifying its revenue base.
Regulatory Affairs Excellence: Staffing and Performance in Medical Device Com...Best Practices
Regulatory affairs group ensure that medical device companies comply with volatile regulatory environment pertaining to developing and marketing medical device products. These specialized groups rely on their own internal effectiveness and efficiencies for enhanced performance under stringent compliance norms. Also, optimal resourcing and staffing helps Regulatory Affairs groups in the medical device industry prioritize roles and responsibilities that will be most beneficial to growth.
Best Practices, LLC conducted this benchmarking study to establish meaningful metrics and insights around the structure, activities, roles and responsibilities of Regulatory Affairs groups at medical device companies. The study also provides recent spend and staffing trends of regulatory affairs in medical device sector, including the use of outsourcing and off-shoring.
Medical device regulatory leaders can use this study to align their staff as per strategies of best in class companies for an increased performance delivery.
This document provides guidance for submitting regulatory submissions of content of labeling to the FDA in electronic format using Structured Product Labeling (SPL), an XML-based standard. It outlines that SPL allows for more efficient exchange and review of labeling information compared to PDF. It describes how to create SPL files according to HL7 specifications and submit them to the FDA either before or after implementation of an automated system for processing SPL files.
DuPont reported its fourth quarter and full year 2014 earnings. Key points include:
- Q4 operating earnings per share increased 20% year-over-year to $0.71.
- Full year 2014 operating earnings increased 3% to $4.01 per share.
- Sales were down 5% in Q4 and 3% for the full year due to currency impacts, portfolio changes, and lower pricing.
- The company increased its expected cost savings target from its operational redesign to $1.3 billion by 2017.
- DuPont reaffirmed its plans to separate the Performance Chemicals segment and return proceeds to shareholders.
- DuPont reported Q4 2014 earnings that exceeded expectations, with operating EPS of $0.71 vs. $0.59 in Q4 2013. Full year 2014 operating EPS was $4.01.
- Segment operating earnings grew 8% in Q4 driven by gains in Agriculture, Performance Materials, and lower costs, partially offset by weaker results in other segments.
- For the full year, net sales declined 3% to $34.7 billion due to currency impacts, portfolio changes, and lower local prices, though volume grew 1%.
- The company continued progress on its portfolio transformation and cost-cutting initiatives while returning $2 billion to shareholders in share repurchases.
ISR interviewed 13 experienced Regulatory Affairs professionals at 11 of the Top 50 pharmaceutical companies to better understand the Regulatory Affairs function. ISR has designed this report to be used as a benchmarking tool for companies to compare their Regulatory Affairs functions to those of other organizations. Key takeaways include:
Identify how your company’s approach to Regulatory Affairs may be different from a typical industry approach and the benefits and drawbacks that may result
Gather information on unique Regulatory Affairs structures and best practices employed by other organizations, which may be used to improve or streamline the function
Compare your company’s Regulatory Affairs department size, structure, resources and approach to those of other companies
Learn more: https://goo.gl/
Transforming Business with Advanced AnalyticsIntel IT Center
The document discusses Intel's new Xeon E7 v2 processor family, which provides significantly better performance and lower total cost of ownership for in-memory analytics workloads compared to IBM Power processors. Key capabilities of the Xeon E7 v2 include up to 2x higher performance, 3x greater memory capacity, 4x higher I/O bandwidth, and reliability features. It established 20 new world records across various analytics benchmarks for 2-socket, 4-socket, and 8-socket configurations. The processor is aimed at transforming businesses through advanced analytics in industries like retail, healthcare, and manufacturing.
This document provides an overview of active pharmaceutical ingredients (APIs). It defines APIs as the chemicals used to manufacture drugs and discusses their production processes, which can include chemical synthesis, fermentation, and extraction from natural sources. The document also lists some of the largest API manufacturers in the world, including Teva, Dr. Reddy's, Aurobindo, Cipla, Sandoz, Ranbaxy, and Sun Pharma. It notes that APIs must meet strict regulatory standards and that many companies outsource API production to locations in Asia.
35th Annual J.P. Morgan Healthcare Conference PresentationCardinal_Health
George S. Barrett, Chairman and CEO of Cardinal Health, gave a presentation at the 35th Annual J.P. Morgan Healthcare Conference on January 9, 2017. In the presentation, Barrett discussed how Cardinal Health is changing healthcare by bringing scaled solutions to help customers navigate a complex industry. He outlined key trends shaping the next five years in healthcare and how Cardinal Health is positioned for growth and success through strategic priorities that align with these trends. Barrett also reviewed Cardinal Health's financial performance and goals over the past five years.
The document describes an automatic vibratory feeder and de-oiling machine from Labh Group of Companies. Labh Group is a renowned manufacturer and exporter of snack food processing and packaging machines located in India. The automatic vibratory feeder and de-oiling machine is designed for high-quality and efficient snack food production. Labh Group has over 20 years of experience in the snack food industry and produces machines to the highest standards with food-grade materials.
Este documento presenta el análisis de los algoritmos de búsqueda primero a lo ancho y primero a lo largo como métodos de búsqueda en un k-árbol. Propone códigos en Mathematica para implementar estos algoritmos, los cuales permiten al usuario ingresar los parámetros de un k-árbol y buscar un dato en él para verificar si se encuentra. El código genera el k-árbol, realiza el recorrido correspondiente al algoritmo seleccionado e imprime el resultado de la búsqueda.
This document describes an automatic air flow puffing machine from Labh Group of Companies. Labh Group is a manufacturer and exporter of snack food processing and packaging machines located in India. The puffing machine uses high-quality mechanical and electronic parts to continuously produce snacks using an automated process. Labh Group has over 20 years of experience in the snack food industry and supplies equipment to customers in over 100 countries globally.
Laughing our way to a better world - TEDxBarcelona 4th april 2013Sindre Edland-Gryt
This document contains 10 photos from various sources such as the UN, Feed My Starving Children, and individuals under Creative Commons licenses. It also includes a short video and a quote about comedy being a "verbal magic trick" attributed to Dr. Lyle Conrad in the public domain. The bulk of the content is photos with varying licenses for non-commercial reuse and redistribution.
This document is about an automatic online grinding machine called LN-352 from Labh Group of Companies. Some key details:
- Labh Group is a manufacturer and exporter of snacks food processing and packaging machines from India.
- The LN-352 is an automatic online grinding machine that is simple to operate and maintain, made with food-grade materials, and designed for continuous running.
- Labh Group has over 20 years of experience in the snacks food industry and supplies advanced machinery globally from its manufacturing facility in India.
Situated in Rajkot, Gujarat, MEFGI aims to create leaders of tomorrow who can face the dynamic society and contribute in increasing the worth of country. MEFGI believes in overall personality development of students. At present the institute is offering under graduate, post graduate and P.hd academic programme. Life at MEFGI is not limited to academic books only. The curriculum of the institute is designed in such a way which gives various opportunities to the students to showcase their talent. The institute is affiliated from Gujarat Technological University and AICTE.
Naveen Kumar Gupta is seeking a job that utilizes his skills and allows him to grow. He has worked as an End User Computing Engineer at Wipro InfoTech since 2015 where he provided IT support, troubleshooting, and access management. He has a B.Tech in computer science and is a certified Microsoft IT Professional. His technical skills include programming, hardware, networking, and Windows/Linux and he is a team player, good learner, and positive thinker.
ISO standards for identification of medical products (IDMP) are set to require pharmaceuticals companies to comply with medicinal identification standards. We explain how to get started and navigate a smooth IDMP transition.
Solutions to Accelerate Compliance with Affordable Care Act (ACA) Mandates an...Lightwell
The healthcare payer ecosystem in the United States has changed dramatically over the last decade and is expected to evolve at an even faster pace over the next few years. Many world-class companies involved in healthcare payment processing are finding themselves constrained by their existing information technology infrastructure. The silos that they built around Business to Business (B2B) processing are constraining them, making it difficult to achieve governmental mandates and (more importantly) increase processing efficiency and competitive advantage.
The payers’ world today requires adherence to multiple industry standards, government regulations, and industry expectations. It is becoming more technical and payers need to become more agile (Figure 1). The IBM Standards Processing Engine Solution for Healthcare Payers is your answer to B2B enablement in today’s complex HIPAA/ACA (Affordable Care Act) world.
This document provides guidance for submitting regulatory submissions of content of labeling to the FDA in electronic format using Structured Product Labeling (SPL), an XML-based standard. It outlines that SPL allows for more efficient exchange and review of labeling information compared to PDF. It describes how to create SPL files according to HL7 specifications and submit them to the FDA either before or after implementation of an automated system for processing SPL files.
DuPont reported its fourth quarter and full year 2014 earnings. Key points include:
- Q4 operating earnings per share increased 20% year-over-year to $0.71.
- Full year 2014 operating earnings increased 3% to $4.01 per share.
- Sales were down 5% in Q4 and 3% for the full year due to currency impacts, portfolio changes, and lower pricing.
- The company increased its expected cost savings target from its operational redesign to $1.3 billion by 2017.
- DuPont reaffirmed its plans to separate the Performance Chemicals segment and return proceeds to shareholders.
- DuPont reported Q4 2014 earnings that exceeded expectations, with operating EPS of $0.71 vs. $0.59 in Q4 2013. Full year 2014 operating EPS was $4.01.
- Segment operating earnings grew 8% in Q4 driven by gains in Agriculture, Performance Materials, and lower costs, partially offset by weaker results in other segments.
- For the full year, net sales declined 3% to $34.7 billion due to currency impacts, portfolio changes, and lower local prices, though volume grew 1%.
- The company continued progress on its portfolio transformation and cost-cutting initiatives while returning $2 billion to shareholders in share repurchases.
ISR interviewed 13 experienced Regulatory Affairs professionals at 11 of the Top 50 pharmaceutical companies to better understand the Regulatory Affairs function. ISR has designed this report to be used as a benchmarking tool for companies to compare their Regulatory Affairs functions to those of other organizations. Key takeaways include:
Identify how your company’s approach to Regulatory Affairs may be different from a typical industry approach and the benefits and drawbacks that may result
Gather information on unique Regulatory Affairs structures and best practices employed by other organizations, which may be used to improve or streamline the function
Compare your company’s Regulatory Affairs department size, structure, resources and approach to those of other companies
Learn more: https://goo.gl/
Transforming Business with Advanced AnalyticsIntel IT Center
The document discusses Intel's new Xeon E7 v2 processor family, which provides significantly better performance and lower total cost of ownership for in-memory analytics workloads compared to IBM Power processors. Key capabilities of the Xeon E7 v2 include up to 2x higher performance, 3x greater memory capacity, 4x higher I/O bandwidth, and reliability features. It established 20 new world records across various analytics benchmarks for 2-socket, 4-socket, and 8-socket configurations. The processor is aimed at transforming businesses through advanced analytics in industries like retail, healthcare, and manufacturing.
This document provides an overview of active pharmaceutical ingredients (APIs). It defines APIs as the chemicals used to manufacture drugs and discusses their production processes, which can include chemical synthesis, fermentation, and extraction from natural sources. The document also lists some of the largest API manufacturers in the world, including Teva, Dr. Reddy's, Aurobindo, Cipla, Sandoz, Ranbaxy, and Sun Pharma. It notes that APIs must meet strict regulatory standards and that many companies outsource API production to locations in Asia.
35th Annual J.P. Morgan Healthcare Conference PresentationCardinal_Health
George S. Barrett, Chairman and CEO of Cardinal Health, gave a presentation at the 35th Annual J.P. Morgan Healthcare Conference on January 9, 2017. In the presentation, Barrett discussed how Cardinal Health is changing healthcare by bringing scaled solutions to help customers navigate a complex industry. He outlined key trends shaping the next five years in healthcare and how Cardinal Health is positioned for growth and success through strategic priorities that align with these trends. Barrett also reviewed Cardinal Health's financial performance and goals over the past five years.
The document describes an automatic vibratory feeder and de-oiling machine from Labh Group of Companies. Labh Group is a renowned manufacturer and exporter of snack food processing and packaging machines located in India. The automatic vibratory feeder and de-oiling machine is designed for high-quality and efficient snack food production. Labh Group has over 20 years of experience in the snack food industry and produces machines to the highest standards with food-grade materials.
Este documento presenta el análisis de los algoritmos de búsqueda primero a lo ancho y primero a lo largo como métodos de búsqueda en un k-árbol. Propone códigos en Mathematica para implementar estos algoritmos, los cuales permiten al usuario ingresar los parámetros de un k-árbol y buscar un dato en él para verificar si se encuentra. El código genera el k-árbol, realiza el recorrido correspondiente al algoritmo seleccionado e imprime el resultado de la búsqueda.
This document describes an automatic air flow puffing machine from Labh Group of Companies. Labh Group is a manufacturer and exporter of snack food processing and packaging machines located in India. The puffing machine uses high-quality mechanical and electronic parts to continuously produce snacks using an automated process. Labh Group has over 20 years of experience in the snack food industry and supplies equipment to customers in over 100 countries globally.
Laughing our way to a better world - TEDxBarcelona 4th april 2013Sindre Edland-Gryt
This document contains 10 photos from various sources such as the UN, Feed My Starving Children, and individuals under Creative Commons licenses. It also includes a short video and a quote about comedy being a "verbal magic trick" attributed to Dr. Lyle Conrad in the public domain. The bulk of the content is photos with varying licenses for non-commercial reuse and redistribution.
This document is about an automatic online grinding machine called LN-352 from Labh Group of Companies. Some key details:
- Labh Group is a manufacturer and exporter of snacks food processing and packaging machines from India.
- The LN-352 is an automatic online grinding machine that is simple to operate and maintain, made with food-grade materials, and designed for continuous running.
- Labh Group has over 20 years of experience in the snacks food industry and supplies advanced machinery globally from its manufacturing facility in India.
Situated in Rajkot, Gujarat, MEFGI aims to create leaders of tomorrow who can face the dynamic society and contribute in increasing the worth of country. MEFGI believes in overall personality development of students. At present the institute is offering under graduate, post graduate and P.hd academic programme. Life at MEFGI is not limited to academic books only. The curriculum of the institute is designed in such a way which gives various opportunities to the students to showcase their talent. The institute is affiliated from Gujarat Technological University and AICTE.
Naveen Kumar Gupta is seeking a job that utilizes his skills and allows him to grow. He has worked as an End User Computing Engineer at Wipro InfoTech since 2015 where he provided IT support, troubleshooting, and access management. He has a B.Tech in computer science and is a certified Microsoft IT Professional. His technical skills include programming, hardware, networking, and Windows/Linux and he is a team player, good learner, and positive thinker.
ISO standards for identification of medical products (IDMP) are set to require pharmaceuticals companies to comply with medicinal identification standards. We explain how to get started and navigate a smooth IDMP transition.
Solutions to Accelerate Compliance with Affordable Care Act (ACA) Mandates an...Lightwell
The healthcare payer ecosystem in the United States has changed dramatically over the last decade and is expected to evolve at an even faster pace over the next few years. Many world-class companies involved in healthcare payment processing are finding themselves constrained by their existing information technology infrastructure. The silos that they built around Business to Business (B2B) processing are constraining them, making it difficult to achieve governmental mandates and (more importantly) increase processing efficiency and competitive advantage.
The payers’ world today requires adherence to multiple industry standards, government regulations, and industry expectations. It is becoming more technical and payers need to become more agile (Figure 1). The IBM Standards Processing Engine Solution for Healthcare Payers is your answer to B2B enablement in today’s complex HIPAA/ACA (Affordable Care Act) world.
The webinar covered key elements of CMS's final rule on covered outpatient drugs, including changes to how Average Manufacturer Price (AMP) will be calculated. Some major points included: territories like Puerto Rico will be included in AMP and rebate calculations starting in 2017; the "presumed inclusion" approach for calculating AMP will remain; and CMS provided clarification on including specialty pharmacies and home infusion providers in the definition of retail community pharmacies. The final rule impacts AMP methodology and data collection, as manufacturers have just over two months to comply with changes to calculate and report AMP. Government programs professionals will play an important role in understanding the rule's implications and ensuring compliance.
Recommendation for PharmaLedger governance, operating model and ConstitutionPharmaLedger
PharmaLedger is a project under the auspices of the Innovative Medicines Initiative (“IMI”). Like all projects, IMI PharmaLedger has a start and an end. The IMI PharmaLedger project will conclude in December 2022. For the solutions developed in PharmaLedger to continue to operate and evolve into the future, we must define a sustainable “post-PharmaLedger” governance and operating model. For the purpose of this report, we are referring to the current project as “IMI PharmaLedger” and the future, post-IMI business network as “NextGen PharmaLedger.”
This document builds on our previous work in researching governance and operation models (“D4.1 PharmaLedger Governance Options”). We provide a summary of the different governance options that we considered and make a recommendation for NextGen PharmaLedger’s future governance and operating model. In some cases there is not yet enough certainty about the scope, participants and scale of NextGen PharmaLedger to make a final recommendation. In those cases, we have narrowed the options to a smaller preferred set but have left a final recommendation until later in the project.
This report does not detail the implementation of its recommendations as those details will come later. Furthermore, it is assumed that the reader has a general familiarity with the governance of blockchain business networks and we do not provide exhaustive explanations of all details contained in this document.
Scenario A specialty memory chip manufacturer is located in South.docxkenjordan97598
Here are three strategic goals that align with the vision and mission statements:
1. Improve quality of care by investing in advanced medical technology and equipment. This supports the mission of providing quality services and the vision of becoming the leading healthcare provider in the region.
2. Expand patient services to include primary care, dental, behavioral health and community outreach programs. This will help achieve the mission of educating the public and the vision of growing the facility over time.
3. Develop strategic partnerships with insurance companies and government organizations to increase patient volume and ensure financial sustainability. This supports both the mission of serving the local community and the vision of a larger, more profitable facility in the long run.
The Drug Quality and Security Act grants the FDA more authority to regulate compounded drugs in response to a 2012 meningitis outbreak. The Act requires serialization of drug products, with serial numbers encoded in 2D barcodes by certain deadlines. This increases tracking of drugs throughout the supply chain. SAP Advanced Track and Trace for Pharmaceuticals provides a single platform to manage serial numbers, integrate serialization into business processes, simplify regulatory reporting to different countries, and scale to handle increasing serialization data volumes.
This document provides guidance for physicians on selecting and implementing an electronic health record (EHR) system. It recommends that physicians take ownership of the selection process, determine their own practice requirements, consider specialty-specific needs, integrate practice management functions, focus on ease-of-use, assess support and upgrades, budget appropriately, and evaluate the vendor's viability long-term. The document also provides an overview of meaningful use requirements and incentives available from Medicaid.
This Discussion offers you the opportunity to apply return on in.docxgasciognecaren
This Discussion offers you the opportunity to apply return on investment (ROI) concepts in a real case scenario. As is often the case, technology offerings involve costs that must be justified by virtue of expense reductions for revenue increases in the organization. There are creative opportunities in the Discussion for leaders to facilitate the development of the revenues into the organization and operational changes that reduce expenses.
Scenario:
Dynamic Health System is a 3-hospital, 500-bed system in the Midwest United States. This system employs 100 physicians, both primary care and specialists, in 12 physician practices. Dynamic also runs a center of excellence in orthopedic care for the large geriatric population in the area, including an outpatient rehabilitation facility that is currently profitable. Dynamic offers a full spectrum of medical and surgical services to their population with an emphasis on programs of excellence in orthopedic surgery, diabetes, and women’s care.
Dynamic’s typical patient mix is over 45% Medicare with another 35% private pay patients covered by three large insurance companies. Their Medicaid population is approximately 12%, with the reminder of patients self-pay.
Due to market forces, the three private payers have begun to implement a program of bundled payments for their members in the following areas: hip replacements, knee replacements, and lower back surgeries. In these models, Dynamic hospitals and employed physicians will be paid a fixed amount for an entire episode of care from pre- surgery evaluation, through surgery and post-surgery, physical therapy, and rehabilitation. Medicare is likewise proposing a pilot study for a population of hip replacement beneficiaries to assess the outcomes of care as opposed to procedure costs as a result of Dynamic’s petition to receive increased payments for beneficiaries due to age demographics and for being the only orthopedic geriatric center in 200 miles.
As a result of these factors and the aging HIT infrastructure, the Chief Medical Officer (CMO), Chief Executive Officer (CEO), and Chief Information Officer (CIO) of Dynamic are proposing the purchase of a monolithic Electronic Health Record (EMR) solution that will provide complete online documentation, orders, pharmacy, labs, and patient portal for all hospitals and employed physician offices. Because the (1) physician offices are currently using Epic Corporation’s back office billing system with an outstanding record of accurate coding and short “days in Accounts Receivable” and (2) Epic’s EMR has a high ranking in industry HIT assessments, the executive team is proposing the purchase of Epic’s clinical EMR (documentation, ancillaries, orders, and patient portal).
The CFO is supportive but skeptical, as the Epic bid is approximately $1.5 M to implement the clinical software with a continued $300K per year in software maintenance and support. Current clinical technologies information systems are fra ...
Diplomat investor presentation january 2018DiplomatIR
Diplomat Pharmacy Inc. is transitioning to a broader healthcare company by acquiring PBMs that expand its services. It acquired NPS and LDI, two full-service PBMs, to address unmet market needs across specialty pharmacy. Specialty drugs are growing much faster than traditional drugs, and Diplomat has extensive access to limited distribution drugs. The acquisitions provide a robust PBM platform and complementary products, services, and solutions to accelerate growth.
1. Policy Analysis
Introduction
Organizational policy alignment and adherence to laws and regulations is critical for overall corporate compliance and to decrease organizational risks (patient falls, medication errors, cyber hacks and PHI data breaches, infection control, et cetera). In this assignment, you will select, evaluate, and update one health care provider’s policy related to a significant regulatory risk to the health care organization.
Instructions
Select one of two options:
Option A
If you work for a hospital or health care organization you may select a policy that is of interest to you then follow these assignment instructions:
· Imagine you are a health care administrator at your current employer. Analyze the policy you selected, taking into consideration any recent changes. Evaluate what information and where that information would need to be updated. Propose revisions that are based on current identified standards and/or new guidelines that you have researched in the text or identified in other high-quality sources (that is, journals, government websites, and the like). Analyze the significance of the selected policy updates as it relates to potential litigation. (Why did the policy need updating? What threats do these changes help avoid?) Summarize your perspective on the revisions as well as any additional changes that should be considered. Present your work as an executive summary suitable for distribution to your organization’s board members.
Option B
If you do not work in the industry or do not have access to a health care policy, use the Hahnemann Falls Policy to complete this assignment. Then follow these assignment instructions:
· As you can see, this policy was written in 2012. Now, imagine you are a health care administrator working at the health care organization where this policy originates from. Analyze the policy, taking into consideration the changes in HIPAA and PHI since 2012. Evaluate what information and where that information would need to be updated for a current revision of this document. Locate the areas where you would update or add information to this 2012 version. Propose revisions that are based on current identified standards and/or new guidelines that you have researched in the text or identified in other high-quality sources (that is, journals, government websites, and the like). Analyze the significance of the selected policy updates as it relates to potential litigation. (Why did the policy need updating? What threats do these changes help avoid?) Summarize your perspective on the revisions as well as any additional changes that should be considered. Present your work as an executive summary suitable for distribution to your organization’s board members.
Your paper should be 3–5 pages long and should include a title page and references for a total of 5–7 pages.
Strayer Writing Standards
This course requires the use of Strayer Writing Standards. For assistance and information, please refer to t ...
This document provides instructions for an assignment to evaluate and propose updates to a healthcare organization's policy related to regulatory compliance. Students are asked to either analyze a policy from their own workplace or a sample policy provided. They must identify areas of the policy that need updating based on current standards and guidelines, propose specific revisions, and analyze how the changes would help reduce litigation risks. Students must submit a 3-5 page executive summary of their analysis and recommendations.
Utilizing crm for medical transparency complianceCharudatta Thute
United States of America (USA) implemented Physician Payment Act, as a part of the healthcare reform bill, in February 2013 commonly known as the Sunshine Act. As per the regulations of this bill, data on payments and gifts made to physicians, teaching hospitals by pharmaceutical
and medical device companies must be made public. Healthcare companies use CRM for sales and service management and medical representatives are the key users to capture HCP (Healthcare professionals) centric data. The paper provides an honest approach to cater to Sunshine act related expense management within CRM. It details concept and approach needed to fulfill Sunshine ACT expense management compliance. The concept is based on study of US medical industry transparency guidelines i.e. Sunshine Act and can be leveraged across geographies with similar medical industry regulations and compliance.
The approach also describes first of its kind unique and distinct feature to track and monitor carbon footprint for expenses incurred by sales representatives. By relating carbon emissions to expenses, it helps set up a practice to approach customers through greener means and reduce organizational carbon footprint,
This corporate presentation outlines Symantec's new strategy to strengthen its offerings by investing more in R&D, improving the customer experience, providing right-for-me offerings, and addressing broader customer needs through new integrated modular offerings. The strategy aims to accelerate organic growth above 5% annually and expand operating margins. Symantec will also simplify its organization and go-to-market approach to better serve customers and partners.
This document is an investor presentation for AMN Healthcare that provides an overview of the company. Some key points:
- AMN Healthcare is a leader and innovator in total talent solutions for healthcare, providing staffing, workforce solutions, leadership and physician search, and talent management services.
- Over 60% of AMN's revenue comes from managed services programs (MSPs) where they provide comprehensive staffing and workforce solutions to health systems.
- AMN has transformed from primarily a diversified staffing company in 2008 to a strategic partner providing a full spectrum of innovative workforce solutions to major health systems in 2022.
- They aim to become the total talent solutions partner for clients by enhancing their digital
This document provides information about a book titled "Handbook of Pharmaceutical Manufacturing Formulations: Liquid Products" which is Volume 3 of a 6 volume series. It is authored by Sarfaraz K. Niazi and published by Informa Healthcare USA, Inc. in 2009. The series contains formulations for various pharmaceutical dosage forms including compressed solids, uncompressed solids, liquids, semisolids, over-the-counter products, and sterile products. This volume focuses specifically on liquid product formulations.
The document provides an overview of Diplomat Pharmacy Inc., a specialty pharmacy company. It summarizes that Diplomat is continuing its transition to become a broader healthcare company by acquiring a pharmacy benefit manager (PBM) to expand its services. It also notes that specialty drug growth is far outpacing traditional drugs, and Diplomat has extensive access to limited-distribution drugs which provides a competitive advantage. Adjusted EBITDA and EPS metrics are presented to evaluate operating performance on a non-GAAP basis.
Pharmaceutical companies and SEO search results complianceMarcos Richardson
This paper looks at two search components (from an optimisation perspective and a pharama compliance perspective) that are publicly visible in search engine results: the ‘Title Tag’ and the ‘Description Tag’.
Search results are important because they are the first piece of information a person sees before clicking and entering a web property and should comply with FDA and PMCPA regulations.
SRS for Online Medicine Ordering SystemUmmeKalsoom11
The purpose of this document is to deliver a detailed depiction of the Online Medicine Ordering System. It will explain the function and characteristics of the system, the boundaries, and purpose of the system, and all the external environment restrictions under which the system must operate and react successfully. Both the investors and the developers of the system will use this document for understanding and approval, respectively.
This document discusses Diplomat Pharmacy's financial results and strategies. It summarizes Diplomat's transition to providing broader healthcare services through acquisitions like its PBM acquisition. It also discusses Diplomat's focus on specialty drugs, limited distribution drugs, oncology, and infusion which are driving the pharmacy industry's growth. Finally, it provides an overview of Diplomat's financial performance in recent years which has seen steady revenue and Adjusted EBITDA growth through acquisitions.